Bilia’s Annual General Meeting 2017 Gothenburg, Sweden,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
66
Bilia’s Annual General Meeting 2017

Gothenburg, Sweden, 2017-04-19 12:56 CEST (GLOBE NEWSWIRE) --  

Today’s Annual General Meeting passed the following resolutions:

  • Dividend set at SEK 8 per share
  • Board, Chairman and public accounting firm re-elected
  • Resolution passed approving 2-for-1 stock split
  • Board given renewed mandate to resolve on buy-back/transfer of shares
  • New Articles of Association adopted with adjusted limits for number of shares and share capital
  • Unchanged guidelines for remuneration to Group Management adopted

Accounts and dividend

After adopting the Income Statement and Balance Sheet and the Consolidated Income Statement and Consolidated Balance Sheet, the AGM adopted the proposed cash dividend of SEK 8 per share (7.50). The record date was set at 21 April 2017 and the dividend is expected to be distributed through Euroclear on 26 April. The remaining earnings were carried forward to a new account.

Discharge from liability and re-election of Board of Directors and public accounting firm

The AGM discharged the members of the Board and the Managing Director from liability for the financial year. The AGM resolved to re-elect Ingrid Jonasson Blank, Eva Cederbalk, Anna Engebretsen, Jack Forsgren, Laila Freivalds, Mats Holgerson, Gustav Lindner, Jan Pettersson, Mats Qviberg and Jon Risfelt. The AGM also re-elected Mats Qviberg as Chairman. After the meeting, the Board once again appointed Jan Pettersson as Deputy Chairman.

The AGM resolved that the directors’ fees should be as follows: the Chairman and the Deputy Chairman of the Board receive SEK 335,000 each, other Board members receive SEK 210,000 each, the chairman of the Audit Committee receives SEK 80,000, the members of the Audit Committee receive SEK 40,000 each, the chairman of the Compensation Committee receives SEK 25,000 and the members of the Compensation Committee receive SEK 10,000 each. The above entails fee increases of SEK 15,000 each for the Chairman and Deputy Chairman, SEK 10,000 each for the other Board members and SEK 5,000 each for the members of the Audit Committee, and no change for the Compensation Committee.

KPMG AB was re-elected as the public accounting firm for the period up until the next AGM in 2018.

2:1 stock split

The AGM passed a resolution to divide the company’s outstanding shares so that each existing share is split into 2 new shares. The record date for the stock split was set at 7 June 2017. Shareholders do not have to take any action to participate in the stock split.

New Articles of Association

New Articles of Association were adopted with adjusted limits for number of shares and share capital, an additional location for the General Meeting of Shareholders and some minor corrections.

Guidelines for remuneration to Group Management

Proposed guidelines for remuneration to the Group Management were adopted by the AGM. The guidelines are virtually unchanged from last year.

Acquisition or transfer of own shares

The AGM authorised the Board of Directors to a) resolve to buy back the company’s own shares, whereby Bilia’s holding may never exceed 10% of the total number of shares at any given time, and b) resolve to transfer acquired shares, either as a means of payment in conjunction with an acquisition or by direct sale on the stock exchange.

Gothenburg, 19 April 2017

Bilia AB (publ)

         For further information, please contact CEO Per Avander or CFO Gunnar Blomkvist,          Bilia AB, tel: +46 31 709 55 00.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading